[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 12, 2007, Pages 1915-1924

  Berriolo Riedinger, Alina ^a,c   Touzery, Claude ^a   Riedinger, Jean Marc ^a   Toubeau, Michel ^a   Coudert, Bruno ^a   Arnould, Laurent ^a   Boichot, Christophe ^a   Cochet, Alexandre ^a   Fumoleau, Pierre ^a   Brunotte, François ^a,b  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c NONE   (France)

Author keywords

18F fluorodeoxyglucose; Breast cancer; Monitoring therapy; PET scan; SUV

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; HORMONE RECEPTOR; TRASTUZUMAB; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DNA POLYMORPHISM; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MITOSIS RATE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PROGNOSIS; TREATMENT RESPONSE; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 36749069360     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0459-5     Document Type: Article

References (39)

1. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
2. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306.
3. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986;46:2578-81.
4. Machiavelli MR, Romero AO, Perez JE, Lacava JA, Dominguez ME, Rodriguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-31.
5. Heller W, Mazhar D, Ward R, Sinnett HD, Lowdell C, Phillips R, et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer. Oncol Rep 2007;17:253-9.
6. Sarid D, Ron IG, Sperber F, Stadler Y, Kahan P, Kovner F, et al. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study. Clin Drug Investig 2006;26:691-701.
7. Dieras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22:4958-65.
8. Warburg O, Wind F, Neglers E. On the metabolism of tumors in the body. In: Warburg O, editor. Metabolism of tumors. London: Constable; 1930. p. 264-70.
9. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257-68.
10. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000;27:861-6.
11. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996;14:700-8.
12. 18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000;1:156-61.
13. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
14. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
15. 18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7.
16. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82.
17. UICC. TNM classification of malignant tumours. Sobin LH, Wittekind C, editors. 2002.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
19. Browne J, Depierro AR. A row-acting alternative to the EM algorithm for maximizing likelihoods in emission tomography. IEEE Trans Ed Imaging 1996;15:687-99.
20. Adam LE, Karp JS, Daube-Witherspoon ME, Smith RJ. Performance of a whole-body PET scanner using curve-plate NaI(Tl) detectors. J Nucl Med 2001;42:1821-30.
21. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-70.
22. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994;35:164-7.
23. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 1993;34:1-6.
24. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916;17:863-71.
25. Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Nanasawa T, Matsuo K, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 2001;96:66-73.
26. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88.
27. 18F]-fluorodeoxyglucose positron emission tomography. Eur J Cancer 2002;38:375-9.
28. 18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366-72.
29. Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12.
30. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005;92:147-55.
31. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53.
32. Kostakoglu L, Agress H Jr, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003;23:315-40.
33. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005;35:84-99.
34. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996;11:235-45.
35. 18F]2-deoxy-2- fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 2004;5:273-8.
36. 18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-34.
37. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-23.
38. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997;80:2505-9.
39. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639-47.